ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Eli Lilly & Co. announced it is halting development of one of its experimental late-stage Alzheimer’s disease treatments because two preliminary Phase III clinical trials indicate that the drug may worsen cognition and the ability to perform daily tasks. The developmental drug, semagacestat, is a γ-secretase inhibitor of amyloid-β, a peptide responsible for plaques that form on the brains of Alzheimer’s patients (C&EN, April 5, page 12). The company says its decision does not affect the Phase III clinical trials of its other Alzheimer’s candidate, solanezumab.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter